Poland · Delayed Price · Currency is PLN BioMaxima Statistics
Total Valuation
BioMaxima has a market cap or net worth of PLN 37.44 million. The enterprise value is 52.92 million.
| Market Cap | 37.44M |
| Enterprise Value | 52.92M |
Important Dates
The next confirmed earnings date is Monday, November 30, 2026.
| Earnings Date | Nov 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioMaxima has 4.19 million shares outstanding.
| Current Share Class | 4.19M |
| Shares Outstanding | 4.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 30.83% |
| Owned by Institutions (%) | n/a |
| Float | 2.26M |
Valuation Ratios
The trailing PE ratio is 46.29.
| PE Ratio | 46.29 |
| Forward PE | n/a |
| PS Ratio | 0.64 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | 31.20 |
| P/OCF Ratio | 19.38 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.53, with an EV/FCF ratio of 43.58.
| EV / Earnings | 67.33 |
| EV / Sales | 0.90 |
| EV / EBITDA | 10.53 |
| EV / EBIT | 38.52 |
| EV / FCF | 43.58 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.52 |
| Quick Ratio | 0.77 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 3.22 |
| Debt / FCF | 13.34 |
| Interest Coverage | 1.16 |
Financial Efficiency
Return on equity (ROE) is 1.69% and return on invested capital (ROIC) is 1.83%.
| Return on Equity (ROE) | 1.69% |
| Return on Assets (ROA) | 1.12% |
| Return on Invested Capital (ROIC) | 1.83% |
| Return on Capital Employed (ROCE) | 2.32% |
| Weighted Average Cost of Capital (WACC) | 6.06% |
| Revenue Per Employee | 424,042 |
| Profits Per Employee | 5,657 |
| Employee Count | 143 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 2.23 |
Taxes
In the past 12 months, BioMaxima has paid 172,000 in taxes.
| Income Tax | 172,000 |
| Effective Tax Rate | 17.53% |
Stock Price Statistics
The stock price has decreased by -33.89% in the last 52 weeks. The beta is 0.33, so BioMaxima's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -33.89% |
| 50-Day Moving Average | 9.95 |
| 200-Day Moving Average | 10.75 |
| Relative Strength Index (RSI) | 12.36 |
| Average Volume (20 Days) | 2,433 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioMaxima had revenue of PLN 60.64 million and earned 809,000 in profits. Earnings per share was 0.19.
| Revenue | 60.64M |
| Gross Profit | 29.29M |
| Operating Income | 1.41M |
| Pretax Income | 981,000 |
| Net Income | 809,000 |
| EBITDA | 4.44M |
| EBIT | 1.41M |
| Earnings Per Share (EPS) | 0.19 |
Balance Sheet
The company has 1.20 million in cash and 16.67 million in debt, with a net cash position of -15.48 million or -3.69 per share.
| Cash & Cash Equivalents | 1.20M |
| Total Debt | 16.67M |
| Net Cash | -15.48M |
| Net Cash Per Share | -3.69 |
| Equity (Book Value) | 48.33M |
| Book Value Per Share | 11.53 |
| Working Capital | 9.77M |
Cash Flow
In the last 12 months, operating cash flow was 2.01 million and capital expenditures -762,000, giving a free cash flow of 1.25 million.
| Operating Cash Flow | 2.01M |
| Capital Expenditures | -762,000 |
| Depreciation & Amortization | 3.02M |
| Net Borrowing | -3.27M |
| Free Cash Flow | 1.25M |
| FCF Per Share | 0.30 |
Margins
Gross margin is 48.30%, with operating and profit margins of 2.33% and 1.33%.
| Gross Margin | 48.30% |
| Operating Margin | 2.33% |
| Pretax Margin | 1.62% |
| Profit Margin | 1.33% |
| EBITDA Margin | 7.31% |
| EBIT Margin | 2.33% |
| FCF Margin | 2.06% |
Dividends & Yields
BioMaxima does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 2.16% |
| FCF Yield | 3.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioMaxima has an Altman Z-Score of 2.53 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.53 |
| Piotroski F-Score | 8 |